Five private medical insurers in the UK now cover Immunoscore® providing patients with localised colon cancer access to this personalised and precision medical tool
HalioDx, the immuno-oncology diagnostic company with whom we partner, has announced that the Clinical Coding & Schedule Development (CCSD) Working Group has recognised the utility and robustness of the Immunoscore® assay by granting it a diagnostic CCSD code (code: 0002T), after reviewing the clinical evidence of Immunoscore® bringing practice changing of oncologists’ post-surgical chemotherapy decisions for stage II and III colon cancer patients.
“Obtaining this CCSD code is a crucial step towards making the Immunoscore more accessible to colon cancer patients in the UK market.“ said Vincent Fert, CEO of HalioDx. ”We are pursuing similar efforts in Europe, Asia and in the US to make Immunoscore® accessible to patients and oncologists for risk-assessment and appraisal of potential benefits of adjuvant chemotherapy.”
To date, five of the main private health insurers in the UK have agreed to cover all their insured patients with stage II and III colon cancer corresponding to over 4 million English lives and accounts for 65% of the insured market.
This achievement is a result of a successful collaboration with HalioDx partner, Everything Genetic Ltd, who are the exclusive distributor and promoter of the Immunoscore® test in the UK market.
“Having major private health insurers now cover Immunoscore® for all stage II and III colon cancer patients indicates three key points: firstly that the significant need for better risk stratification for this large group of patients and the general trend to understand a persons risk of recurrent cancer, secondly the immune response is a main indicator, and also that the solid and sizable data sets behind the international Immunoscore® validation study. This assay is simply ground breaking and unlike any other and a major focus for EGL going into 2020 and beyond.” added, James Price, CEO of Everything Genetic.
Immunoscore® is a risk-assessment tool in localised colon cancer that provides independent and superior prognostic value than the usual tumor risk parameters, and should be used as an adjunct to the TNM classification (Pagès F et al. The Lancet 2018, Sinicrope F et al. JCO 2018 36.4 suppl; 614). In addition, Immunoscore® is predictive of response to chemotherapy in stage III patients and helps to define the optimal duration of adjuvant treatment (Pagès F et al JCO 2019 37.17 suppl; 3513 ).
If you are a clinician and would like to find out more about the Immunoscore® test, please contact James Price on +44 (0) 1270 623 179.
Immunoscore® is a unique family of immune-based tests ranging from full IVD such as Immunoscore® for colon cancer, fulfilling the most stringent regulation such as CE IVD conformity and CLIA certification, to Immunoscore® for Clinical Research suite of tests applicable to clinical investigations. It includes proprietary multiplexed immunohistochemistry, advanced image analysis and spatially resolved capabilities. By precisely quantifying immune cell infiltration in and around the tumor, Immunoscore® has already proven its superior prognostic value than the usual tumor risk parameters notably in colon cancer. Today, Immunoscore® is investigated in a broad number of studies for establishing its performances as predictive factor for response to cancer drugs, including immunotherapies.